Healthcare Providers and Services
Company Overview of University Health Network
University Health Network provides patient care, education, and research services in Canada. The company operates four hospital sites, including Princess Margaret Hospital, Toronto General Hospital, Toronto Western Hospital, and Toronto Rehabilitation Institute. Its Princess Margaret Hospital offers diagnostic, treatment, and follow-up care services in medical, surgical, and radiation oncology areas with 12 site groups and 26 specialty clinics. The company’s Toronto General Hospital provides services in the areas of cardiac care, organ transplants, and the treatment of complex patient needs. Its Toronto Western Hospital offers services in the areas of neuroscience, musculoskeletal health, an...
190 Elizabeth Street
Toronto, ON M5G 2C4
Key Executives for University Health Network
Chief Executive Officer and President
Medical Director of the Medicine and Community Health Program
Director of Technology Development and Commercialization
Compensation as of Fiscal Year 2014.
University Health Network Key Developments
Generex Biotechnology Corp. Collaborates with University Health Network for Buccal Insulin Project
Sep 22 14
Generex Biotechnology Corporation announced that it has entered into a collaboration with University Health Network (UHN) pursuant to which UHN's Centre for Molecular Design and Preformulations (CMDP) will spearhead the Company's buccal insulin refinement project. The goal of the project is to increase the insulin bioavailability of Generex Oral-lyn(TM), the Company's proprietary buccal insulin spray product, thereby reducing the number of puffs required to achieve effective prandial metabolic control for patients with diabetes. This research will ensure the product is more attractive to patients and prospective commercialization partners.
University Health Network Appoints Dr. Peter Pisters as President & Chief Executive Officer
Aug 7 14
University Health Network announced that Dr. Peter Pisters, currently Vice President of The University of Texas MD Anderson Cancer Center's Regional Care System, will serve as UHN's next President & CEO. Dr. Pisters has held a number of clinical, administrative and leadership positions at MD Anderson from 1994 to the present with his most recent executive responsibilities being the management of 6 MD Anderson centers for care across metropolitan Houston. Prior to his current role he was Medical Director of the regional cancer centers, Clinical Consultant for the Center for Global Oncology (now known as MD Anderson Cancer Network), Section Chief for Sarcoma Surgery with a specialty focus in the management of sarcoma and gastrointestinal cancer patients. Dr. Pisters takes on the role of President & CEO of UHN on January 1, 2015.
Sernova Corp. Agrees on Terms with the University Health Network of Toronto to Gain Access to Proprietary Stem Cell Technology for the Treatment of Diabetes
Jul 15 14
Sernova Corp. announced that it has agreed on key terms with the University Health Network of Toronto (UHN) to gain access to worldwide, exclusive rights to certain patent-pending technologies developed by distinguished UHN researchers, Dr. Cristina Nostro and Dr. Gordon Keller, for the advancement of insulin-producing stem cells for the treatment of patients with insulin-dependent diabetes. Sernova and UHN have entered into a Term Sheet with an exclusive negotiation period which outlines the terms of the definitive license agreement for the granting of an exclusive license to Sernova covering all patent rights relating to the UHN stem cell technologies including for the treatment of diabetes. A product development program is also being designed to advance the technologies from preclinical proof-of-concept studies through to human testing on an expedited basis. Sernova believes the proprietary product - insulin producing stem cells, protected locally from immune system attack and placed within Sernova's prevascularized Cell Pouch(TM) - has the potential to provide a significant break-through in the quality of treatment for the millions of people suffering from insulin-dependent diabetes, following successful preclinical and clinical testing. Such individuals could essentially be liberated from their current onerous regime of daily blood glucose testing and insulin administration delivered through injections or electronic means which is expected to materially improve their quality of life while also reducing short term and longer term health care costs.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|